Comparative Pharmacology
Head-to-head clinical analysis: ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE versus LUSEDRA.
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albuterol is a beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle. Ipratropium bromide is an anticholinergic agent that inhibits muscarinic receptors, reducing bronchoconstriction and mucus secretion.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Two inhalations (albuterol 90 mcg and ipratropium 18 mcg per inhalation) four times daily via oral inhalation. Maximum: 12 inhalations per day.
5 mg orally once daily.
None Documented
None Documented
Albuterol: 3-6 hours (terminal half-life), prolonged in hepatic or renal impairment. Ipratropium: 1.5-2 hours (terminal half-life), clinical effects persist longer due to receptor binding.
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Albuterol: 60-70% renal as unchanged drug and metabolites (primarily sulfate conjugate), 10-20% fecal. Ipratropium: 50-60% fecal (unabsorbed), 30-40% renal (metabolites); minimal renal excretion of unchanged drug.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category A/B
Category C
Anticholinergic
Anticholinergic